Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy

Tomokazu Fuji, Yuzo Umeda, Akihiro Nyuya, Fumitaka Taniguchi, Takashi Kawai, Kazuya Yasui, Toshiaki Toshima, Kazuhiro Yoshida, Toshiyoshi Fujiwara, Ajay Goel, Takeshi Nagasaka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Because of the different forms of circulating miRNAs in plasma, Argonaute2 (Ago2)-miRNAs and extracellular vesicles (EV-miRNAs), we examined the two forms of extracellular miRNAs in vitro and developed a unique methodology to detect circulating Ago2-miRNAs in small volumes of plasma. We demonstrated that Ago2-miR-21 could be released into the extracellular fluid by active export from viable cancer cells and cytolysis in vitro. As miR-21 and miR-200c were abundantly expressed in both metastatic liver sites and primary lesions, we evaluated Ago2-miR-21 as a candidate biomarker of both active export and cytolysis while Ago2-miR-200c as a biomarker of cytolysis in plasma obtained from colorectal cancer (CRC) patients before treatment and in a series of plasma obtained from CRC patients with liver metastasis who received systemic chemotherapy. The measurement of Ago2-miR-21 allowed us to distinguish CRC patients from subjects without CRC. The trend in ΔCt values for Ago2-miR-21 and -200c during chemotherapy could predict tumor response to ongoing treatment. Thus, capturing circulating Ago2-miRNAs from active export can screen patients with tumor burdens, while capturing them from passive release by cytolysis can monitor tumor dynamics during chemotherapy treatment.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

MicroRNAs
Colorectal Neoplasms
Drug Therapy
Neoplasms
Biomarkers
Plasma Volume
Liver
Extracellular Fluid
Tumor Burden
Therapeutics
Neoplasm Metastasis

Keywords

  • Ago2
  • chemotherapy
  • circulating miRNA
  • colorectal cancer
  • liquid biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. / Fuji, Tomokazu; Umeda, Yuzo; Nyuya, Akihiro; Taniguchi, Fumitaka; Kawai, Takashi; Yasui, Kazuya; Toshima, Toshiaki; Yoshida, Kazuhiro; Fujiwara, Toshiyoshi; Goel, Ajay; Nagasaka, Takeshi.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Fuji, Tomokazu ; Umeda, Yuzo ; Nyuya, Akihiro ; Taniguchi, Fumitaka ; Kawai, Takashi ; Yasui, Kazuya ; Toshima, Toshiaki ; Yoshida, Kazuhiro ; Fujiwara, Toshiyoshi ; Goel, Ajay ; Nagasaka, Takeshi. / Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. In: International Journal of Cancer. 2019.
@article{d706935b0303460683df6556c5eae4cc,
title = "Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy",
abstract = "Because of the different forms of circulating miRNAs in plasma, Argonaute2 (Ago2)-miRNAs and extracellular vesicles (EV-miRNAs), we examined the two forms of extracellular miRNAs in vitro and developed a unique methodology to detect circulating Ago2-miRNAs in small volumes of plasma. We demonstrated that Ago2-miR-21 could be released into the extracellular fluid by active export from viable cancer cells and cytolysis in vitro. As miR-21 and miR-200c were abundantly expressed in both metastatic liver sites and primary lesions, we evaluated Ago2-miR-21 as a candidate biomarker of both active export and cytolysis while Ago2-miR-200c as a biomarker of cytolysis in plasma obtained from colorectal cancer (CRC) patients before treatment and in a series of plasma obtained from CRC patients with liver metastasis who received systemic chemotherapy. The measurement of Ago2-miR-21 allowed us to distinguish CRC patients from subjects without CRC. The trend in ΔCt values for Ago2-miR-21 and -200c during chemotherapy could predict tumor response to ongoing treatment. Thus, capturing circulating Ago2-miRNAs from active export can screen patients with tumor burdens, while capturing them from passive release by cytolysis can monitor tumor dynamics during chemotherapy treatment.",
keywords = "Ago2, chemotherapy, circulating miRNA, colorectal cancer, liquid biopsy",
author = "Tomokazu Fuji and Yuzo Umeda and Akihiro Nyuya and Fumitaka Taniguchi and Takashi Kawai and Kazuya Yasui and Toshiaki Toshima and Kazuhiro Yoshida and Toshiyoshi Fujiwara and Ajay Goel and Takeshi Nagasaka",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.31960",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy

AU - Fuji, Tomokazu

AU - Umeda, Yuzo

AU - Nyuya, Akihiro

AU - Taniguchi, Fumitaka

AU - Kawai, Takashi

AU - Yasui, Kazuya

AU - Toshima, Toshiaki

AU - Yoshida, Kazuhiro

AU - Fujiwara, Toshiyoshi

AU - Goel, Ajay

AU - Nagasaka, Takeshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Because of the different forms of circulating miRNAs in plasma, Argonaute2 (Ago2)-miRNAs and extracellular vesicles (EV-miRNAs), we examined the two forms of extracellular miRNAs in vitro and developed a unique methodology to detect circulating Ago2-miRNAs in small volumes of plasma. We demonstrated that Ago2-miR-21 could be released into the extracellular fluid by active export from viable cancer cells and cytolysis in vitro. As miR-21 and miR-200c were abundantly expressed in both metastatic liver sites and primary lesions, we evaluated Ago2-miR-21 as a candidate biomarker of both active export and cytolysis while Ago2-miR-200c as a biomarker of cytolysis in plasma obtained from colorectal cancer (CRC) patients before treatment and in a series of plasma obtained from CRC patients with liver metastasis who received systemic chemotherapy. The measurement of Ago2-miR-21 allowed us to distinguish CRC patients from subjects without CRC. The trend in ΔCt values for Ago2-miR-21 and -200c during chemotherapy could predict tumor response to ongoing treatment. Thus, capturing circulating Ago2-miRNAs from active export can screen patients with tumor burdens, while capturing them from passive release by cytolysis can monitor tumor dynamics during chemotherapy treatment.

AB - Because of the different forms of circulating miRNAs in plasma, Argonaute2 (Ago2)-miRNAs and extracellular vesicles (EV-miRNAs), we examined the two forms of extracellular miRNAs in vitro and developed a unique methodology to detect circulating Ago2-miRNAs in small volumes of plasma. We demonstrated that Ago2-miR-21 could be released into the extracellular fluid by active export from viable cancer cells and cytolysis in vitro. As miR-21 and miR-200c were abundantly expressed in both metastatic liver sites and primary lesions, we evaluated Ago2-miR-21 as a candidate biomarker of both active export and cytolysis while Ago2-miR-200c as a biomarker of cytolysis in plasma obtained from colorectal cancer (CRC) patients before treatment and in a series of plasma obtained from CRC patients with liver metastasis who received systemic chemotherapy. The measurement of Ago2-miR-21 allowed us to distinguish CRC patients from subjects without CRC. The trend in ΔCt values for Ago2-miR-21 and -200c during chemotherapy could predict tumor response to ongoing treatment. Thus, capturing circulating Ago2-miRNAs from active export can screen patients with tumor burdens, while capturing them from passive release by cytolysis can monitor tumor dynamics during chemotherapy treatment.

KW - Ago2

KW - chemotherapy

KW - circulating miRNA

KW - colorectal cancer

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85059613677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059613677&partnerID=8YFLogxK

U2 - 10.1002/ijc.31960

DO - 10.1002/ijc.31960

M3 - Article

C2 - 30381824

AN - SCOPUS:85059613677

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -